Chief Technical Ops Officer Sells 9,743 Shares
Focused on next-generation vaccines for bacterial diseases, this biotech just reported a notable insider sale amid a challenging year.
Harpreet S. Dhaliwal, Chief Technical Ops Officer of Vaxcyte (PCVX 2.23%), disposed of 9,743 shares in an open-market sale valued at approximately $454,891 according to the SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 9,743 |
| Transaction value | ~$454,890.93 |
| Post-transaction shares (direct) | 23,928 |
| Post-transaction value (direct ownership) | ~$1,111,694.88 |
Transaction value based on SEC Form 4 weighted average purchase price ($46.69); post-transaction value based on Jan. 2 market close ($46.46).
Key questions
- How significant was this sale in relation to Dhaliwal's prior holdings?
The transaction reduced direct ownership by 28.9%, shifting Dhaliwal's stake from 33,671 shares to 23,928 shares, with no remaining indirect exposure. - Were any derivative, trust, or administrative mechanisms involved?
This was a straightforward open-market sale of common stock with no derivative exercise, trust, or administrative withholdings reported in the filing.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close Jan. 2, 2026) | $46.46 |
| Market capitalization | $6.08 billion |
| Net income (TTM) | -$657.20 million |
| 1-year price change | -44.20% |
* 1-year performance calculated using Jan. 2 as the reference date.
Company snapshot
Vaxcyte is a clinical-stage biotechnology company specializing in the development of next-generation protein vaccines to address unmet medical needs in bacterial infectious disease prevention. With a pipeline led by VAX-24, the company leverages advanced conjugation and protein engineering technologies to expand vaccine coverage and address antibiotic resistance. The strategy centers on innovation in vaccine design and a focus on diseases with significant global health impact, positioning it as a differentiated player in the vaccine development landscape.
- Develops clinical-stage vaccines, including VAX-24 for pneumococcal disease, VAX-XP for emerging strains, VAX-A1 for Group A Strep, and VAX-PG for periodontitis.
- Operates a biotechnology business model focused on research, development, and eventual commercialization of novel protein-based vaccines targeting bacterial infectious diseases.
- Targets healthcare providers, hospitals, and public health agencies seeking advanced vaccine solutions for infectious disease prevention.
What this transaction means for investors
Harpreet Dhaliwal sold a significant portion of his holdings on Dec. 31. The 9,743 share sale represented 28.9% of his holdings.
The transaction comes after a challenging year. The stock price sagged 44.2% over the last year through Jan. 2, while the S&P 500 index returned 18.4% during this period.
Notably, Vaxcyte's shares experienced a sharp drop in late March and early April before modestly recovering. Dhaliwal's transaction could indicate a lack of confidence that the stock price will sustain this momentum.
Vaxcyte doesn't have any approved products in the market, and hence, doesn't produce any revenue. The company lost $520.1 million during the first nine months of 2025.
Monitoring the progress in the approval process will provide a key indicator of the company's success. While you're doing that, following insider transactions can provide clues into directors' and officers' confidence in gaining product approvals.
Glossary
Open-market sale: The sale of securities on a public exchange at prevailing market prices, not through private arrangements.
SEC Form 4: A required filing disclosing insider transactions in a public company’s securities.
Direct holdings: Shares owned personally by an individual, not through trusts or other entities.
Indirect exposure: Ownership or economic interest in shares held via trusts, family members, or other entities.
Derivative activity: Transactions involving financial contracts whose value is based on an underlying asset, such as options or warrants.
Trust attribution: Assigning ownership of shares to an individual through a trust or similar legal arrangement.
Weighted average purchase price: The average price paid per share, calculated by weighting each purchase price by the number of shares bought or sold.
Clinical-stage: Refers to a company or product currently undergoing human clinical trials but not yet approved for commercial sale.
Conjugation: A vaccine technology that links a protein to a polysaccharide to enhance immune response.
Antibiotic resistance: The ability of bacteria to withstand the effects of antibiotics, making infections harder to treat.
Total return: The investment's price change plus all dividends and distributions, assuming those payouts are reinvested.
TTM: The 12-month period ending with the most recent quarterly report.
